Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report.
COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study.
Zebrafish screen identifies novel compound with selective toxicity against leukemia.
Myelination of the nervous system: mechanisms and functions.
MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
Assessment of cerebral venous return by a novel plethysmography method.
Mesenchymal stem cells as treatment for MS - progress to date.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Multiple sclerosis and oligodendroglioma: an exceptional association.
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.
Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis.
Momenta Pharmaceuticals Announces Launch of Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2.
Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy.
DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP).
Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.
Multiple sclerosis causing a partial sixth nerve palsy.
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis.
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
Motor programme activating therapy influences adaptive brain functions in multiple sclerosis: clinical and MRI study.
Optic nerve disease and axon pathophysiology.
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.

Pages